康方生物完成根据一般授权配售一级新股及配售现有股份

Group 1 - The company 康方生物 (09926) announced that all conditions of the primary placement agreement have been met, and the completion of the primary placement was realized on September 4, 2025 [1] - A total of 23.55 million shares were placed by the placement agent at a price of HKD 149.54 per share, representing approximately 2.56% of the company's issued share capital after the placement [1] - The board was informed by Dr. Xia Yu and Dr. Li Baiyong (as sellers) that the secondary placement was completed on September 1, 2025 [1] Group 2 - The placement agent successfully facilitated buyers to purchase a total of 3 million existing shares at the same price of HKD 149.54 per share under the terms of the secondary placement agreement [1]